<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Lanadelumab_Renewal_RenewalCriteria_Q3</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Definition: A response to treatment is defined as a reduction (50% or more reduction) in the average number of HAE attacks per
month for which acute injectable treatment was received within the initial six months of treatment with lanadelumab
compared to the average number of attacks per month observed before initiating treatment with lanadelumab.</questionText>
        <responseValues>Yes
No</responseValues>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>Radio</dataType>
    <developerName>Lanadelumab_Renewal_RenewalCriteria_Q3</developerName>
    <name>Lanadelumab_Renewal_RenewalCriteria_Q3</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
